See more : Micropac Industries, Inc. (MPAD) Income Statement Analysis – Financial Results
Complete financial analysis of Sanofi (SNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sanofi, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Growthpoint Properties Limited (GWWTF) Income Statement Analysis – Financial Results
- Phoenix Media Investment (Holdings) Limited (PXSTF) Income Statement Analysis – Financial Results
- Poynt Corporation (PNYTF) Income Statement Analysis – Financial Results
- Thor Industries, Inc. (THO) Income Statement Analysis – Financial Results
- Xalles Holdings Inc. (XALL) Income Statement Analysis – Financial Results
Sanofi (SNY)
About Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.03B | 45.39B | 39.18B | 37.37B | 37.63B | 35.68B | 36.22B | 34.70B | 34.86B | 32.00B | 31.29B | 35.96B | 35.06B | 32.04B | 30.75B | 28.82B | 29.25B | 29.49B | 28.49B | 15.03B | 8.03B | 7.46B | 6.49B | 5.96B | 5.35B |
| Cost of Revenue | 14.24B | 13.69B | 12.26B | 12.16B | 11.98B | 11.32B | 11.45B | 10.70B | 10.92B | 10.23B | 10.29B | 11.08B | 10.90B | 8.72B | 7.88B | 7.34B | 7.58B | 7.59B | 7.56B | 3.75B | 1.43B | 1.38B | 1.25B | 1.44B | 1.49B |
| Gross Profit | 31.80B | 31.70B | 26.92B | 25.21B | 25.66B | 24.36B | 24.77B | 24.00B | 23.94B | 21.77B | 21.00B | 24.88B | 24.16B | 23.32B | 22.87B | 21.48B | 21.67B | 21.90B | 20.93B | 11.28B | 6.61B | 6.08B | 5.24B | 4.52B | 3.86B |
| Gross Profit Ratio | 69.07% | 69.83% | 68.72% | 67.47% | 68.18% | 68.27% | 68.40% | 69.16% | 68.68% | 68.03% | 67.10% | 69.20% | 68.90% | 72.79% | 74.37% | 74.55% | 74.08% | 74.27% | 73.47% | 75.05% | 82.26% | 81.50% | 80.69% | 75.82% | 72.11% |
| Research & Development | 6.73B | 6.71B | 5.69B | 5.53B | 6.02B | 6.35B | 5.57B | 5.23B | 5.08B | 4.67B | 4.61B | 4.91B | 4.81B | 4.40B | 4.58B | 4.58B | 4.54B | 4.43B | 4.04B | 7.45B | 1.31B | 1.22B | 1.03B | 945.00M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 75.00M | 106.00M | 106.00M | 114.00M | -542.00M | -495.00M | 182.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 9.39B | 9.88B | 9.86B | 10.06B | 9.49B | 9.38B | 9.11B | 8.60B | 8.95B | 8.54B | 7.57B | 7.33B | 7.17B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.77B | 10.54B | 9.56B | 9.39B | 9.88B | 9.93B | 10.16B | 9.59B | 9.50B | 8.57B | 8.11B | 9.13B | 8.54B | 7.57B | 7.33B | 7.17B | 7.87B | 8.02B | 8.24B | 4.50B | 2.47B | 2.43B | 2.31B | 2.02B | 1.89B |
| Other Expenses | 6.45B | 2.57B | 2.53B | 2.40B | 2.53B | 1.70B | 1.66B | 1.65B | 2.23B | 3.02B | 3.13B | 3.02B | 3.62B | 3.58B | 3.14B | -23.00M | 3.20B | 3.45B | 2.93B | -360.73M | -246.94M | -189.64M | -208.00M | -17.00M | 995.00M |
| Operating Expenses | 23.94B | 19.81B | 17.77B | 17.32B | 18.43B | 17.99B | 17.39B | 16.48B | 16.81B | 16.25B | 15.84B | 17.05B | 16.97B | 15.55B | 15.05B | 11.72B | 15.61B | 15.90B | 15.21B | 11.59B | 3.54B | 3.46B | 3.13B | 2.94B | 2.89B |
| Cost & Expenses | 38.16B | -7.29B | 30.03B | 29.48B | 30.41B | -7.73B | -7.42B | -7.18B | -7.44B | -5.64B | -5.86B | -7.29B | 27.87B | 24.27B | 22.93B | 19.06B | 23.20B | 23.49B | 22.77B | 15.34B | 4.96B | 4.84B | 4.38B | 4.39B | 4.38B |
| Interest Income | 546.00M | 206.00M | 40.00M | 53.00M | 141.00M | 164.00M | 147.00M | 68.00M | 178.00M | 193.00M | 109.00M | 93.00M | 140.00M | 105.00M | 24.00M | 65.00M | 190.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.09B | 461.00M | 368.00M | 390.00M | 444.00M | 495.00M | 420.00M | 924.00M | 559.00M | 598.00M | 609.00M | 751.00M | 552.00M | 467.00M | 324.00M | 335.00M | 329.00M | 1.54B | 4.71B | 2.53B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 3.78B | 3.70B | 3.13B | 3.27B | 3.75B | 3.46B | 3.15B | 2.99B | -2.48B | -2.75B | -3.39B | -3.20B | 4.91B | 5.44B | 5.00B | 245.00M | 4.48B | 6.73B | 5.95B | 2.52B | 117.52M | 179.16M | 301.00M | 241.00M | 236.00M |
| EBITDA | 12.00B | 14.06B | 11.29B | 17.51B | 7.11B | 9.36B | 10.28B | 10.36B | 10.23B | 9.87B | 9.62B | 11.43B | 10.64B | 11.40B | 11.40B | 10.48B | 10.40B | 12.12B | 11.67B | 2.25B | 3.19B | 3.00B | 2.41B | 1.82B | 1.21B |
| EBITDA Ratio | 26.06% | 30.98% | 27.47% | 26.13% | 26.15% | 26.24% | 28.38% | 29.86% | 29.36% | 30.84% | 30.74% | 34.77% | 30.35% | 35.59% | 36.98% | 34.73% | 35.56% | 42.26% | 47.01% | 14.99% | 39.67% | 37.49% | 37.10% | 30.49% | 22.56% |
| Operating Income | 7.88B | 16.79B | 8.13B | 8.08B | 7.69B | 12.43B | 12.01B | 12.34B | 12.71B | 12.62B | 13.01B | 15.70B | 5.73B | 5.96B | 6.37B | 9.76B | 5.92B | 5.73B | 7.45B | -262.61M | 3.07B | 2.62B | 2.11B | 1.58B | 971.00M |
| Operating Income Ratio | 17.11% | 37.00% | 20.74% | 21.63% | 20.45% | 34.84% | 33.15% | 35.57% | 36.46% | 39.45% | 41.58% | 43.67% | 16.35% | 18.61% | 20.70% | 33.88% | 20.24% | 19.43% | 26.13% | -1.75% | 38.21% | 35.09% | 32.46% | 26.45% | 18.15% |
| Total Other Income/Expenses | -722.00M | -166.00M | -328.00M | 24.00M | -229.00M | 228.00M | -188.00M | -720.00M | -403.00M | -458.00M | -459.00M | -1.81B | -542.00M | -362.00M | -300.00M | -232.00M | -139.00M | -981.21M | -2.11B | -588.67M | 58.76M | -108.64M | 34.00M | -17.00M | -48.00M |
| Income Before Tax | 7.15B | 10.49B | 7.80B | 13.80B | 2.82B | 4.90B | 5.62B | 5.81B | 5.22B | 5.61B | 4.52B | 6.17B | 5.32B | 5.60B | 6.07B | 9.49B | 5.78B | 4.75B | 2.64B | -1.84B | 3.13B | 2.51B | 2.14B | 1.56B | 0.00 |
| Income Before Tax Ratio | 15.54% | 23.11% | 19.91% | 36.94% | 7.50% | 13.75% | 15.50% | 16.75% | 14.98% | 17.52% | 14.45% | 17.15% | 15.17% | 17.48% | 19.73% | 32.94% | 19.76% | 16.10% | 9.27% | -12.25% | 38.94% | 33.63% | 32.98% | 26.16% | 0.00% |
| Income Tax Expense | 1.60B | 2.01B | 1.56B | 1.81B | 139.00M | 481.00M | 1.72B | 1.33B | 709.00M | 1.21B | 726.00M | 1.11B | 455.00M | 1.24B | 1.36B | 2.76B | 687.93M | 800.12M | 477.04M | 818.09M | 1.06B | 747.13M | 842.00M | 611.00M | 346.00M |
| Net Income | 5.40B | 8.37B | 6.22B | 12.29B | 2.81B | 4.31B | 3.89B | 4.71B | 4.29B | 4.39B | 3.72B | 4.97B | 5.69B | 4.36B | 5.27B | 7.19B | 5.27B | 4.01B | 2.26B | -2.66B | 2.07B | 1.76B | 1.59B | 985.00M | 625.00M |
| Net Income Ratio | 11.73% | 18.44% | 15.89% | 32.90% | 7.46% | 12.07% | 10.75% | 13.57% | 12.30% | 13.72% | 11.88% | 13.81% | 16.24% | 13.60% | 17.12% | 24.94% | 18.02% | 13.58% | 7.92% | -17.70% | 25.80% | 23.61% | 24.43% | 16.52% | 11.68% |
| EPS | 4.31 | 6.69 | 4.97 | 9.81 | 2.33 | 3.45 | 3.08 | 3.42 | 3.38 | 3.25 | 2.75 | 3.70 | 4.27 | 3.34 | 4.03 | 2.94 | 3.91 | 2.97 | 1.68 | -2.92 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| EPS Diluted | 4.30 | 6.66 | 4.95 | 9.76 | 2.31 | 3.43 | 3.07 | 3.39 | 3.34 | 3.21 | 2.71 | 3.68 | 4.26 | 3.33 | 4.03 | 2.94 | 3.89 | 2.95 | 1.67 | -2.91 | 2.95 | 2.42 | 2.17 | 1.35 | 0.85 |
| Weighted Avg Shares Out | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.25B | 1.27B | 1.29B | 1.32B | 1.32B | 1.32B | 1.33B | 1.32B | 1.31B | 1.31B | 1.31B | 1.35B | 1.35B | 1.34B | 910.30M | 702.75M | 727.69M | 731.71M | 731.23M | 730.78M |
| Weighted Avg Shares Out (Dil) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B | 1.32B | 1.33B | 1.34B | 1.33B | 1.33B | 1.31B | 1.31B | 1.31B | 1.35B | 1.36B | 1.35B | 914.80M | 705.12M | 729.27M | 731.71M | 731.23M | 730.78M |
Sanofi enters exclusive talks with CD&R for Opella sale
Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI
SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies
PAI Partners makes higher offer for Sanofi's Opella, says Le Monde
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals
Workers at Sanofi to strike to protest consumer health unit sale, union official says
Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies
Source: https://incomestatements.info
Category: Stock Reports